NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

Search

Roche Holding AG

Aperta

SettoreSettore sanitario

302.2 0.8

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

297.2

Massimo

303.2

Metriche Chiave

By Trading Economics

Entrata

1.7B

3.7B

Vendite

-15B

16B

P/E

Media del settore

22.865

35.739

Rendimento da dividendi

3.62

Margine di Profitto

23.266

Dipendenti

103,249

EBITDA

547M

6.5B

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.62%

3.08%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-368M

205B

Apertura precedente

301.4

Chiusura precedente

302.2

Notizie sul Sentiment di mercato

By Acuity

50%

50%

149 / 371 Classifica in Healthcare

Roche Holding AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 ott 2025, 08:54 UTC

I principali Market Mover

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18 set 2025, 14:01 UTC

Acquisizioni, Fusioni, Takeovers

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18 set 2025, 10:05 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

89bio Shares Soar Premarket on Takeover by Roche

18 set 2025, 10:04 UTC

Acquisizioni, Fusioni, Takeovers

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18 set 2025, 05:37 UTC

Acquisizioni, Fusioni, Takeovers

Roche to Buy 89bio for Up to $3.5 Billion

24 lug 2025, 15:09 UTC

Utili

Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices -- Update

24 lug 2025, 05:36 UTC

Utili

Roche Backs 2025 Views After Strong Sales of Key Drugs

1 ott 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1 ott 2025, 09:05 UTC

Azioni calde

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18 set 2025, 14:12 UTC

Acquisizioni, Fusioni, Takeovers

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18 set 2025, 07:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18 set 2025, 05:09 UTC

Acquisizioni, Fusioni, Takeovers

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

18 set 2025, 05:06 UTC

Acquisizioni, Fusioni, Takeovers

Roche: Deal Is Expected to Close in 4Q

18 set 2025, 05:06 UTC

Acquisizioni, Fusioni, Takeovers

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

18 set 2025, 05:05 UTC

Acquisizioni, Fusioni, Takeovers

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

18 set 2025, 05:05 UTC

Acquisizioni, Fusioni, Takeovers

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

18 set 2025, 05:04 UTC

Acquisizioni, Fusioni, Takeovers

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

18 set 2025, 05:03 UTC

Acquisizioni, Fusioni, Takeovers

Roche: Total Deal Value Is Up to $3.5B

18 set 2025, 05:02 UTC

Acquisizioni, Fusioni, Takeovers

Roche to Buy 89bio

18 set 2025, 05:02 UTC

Acquisizioni, Fusioni, Takeovers

Roche Enters Into Deal to Buy 89bio

8 ago 2025, 10:51 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

8 ago 2025, 07:39 UTC

Discorsi di Mercato
Utili

Roche Could Reach Peak Earnings Growth This Year -- Market Talk

5 ago 2025, 10:40 UTC

Discorsi di Mercato

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

24 lug 2025, 06:52 UTC

Discorsi di Mercato
Utili

Roche Looks Confident in a Tricky Environment -- Market Talk

24 lug 2025, 05:05 UTC

Utili

Roche Backs 2025 View

24 lug 2025, 05:05 UTC

Utili

Correct: Roche 1H Diagnostics Sales Down 3%, Reported

24 lug 2025, 05:04 UTC

Utili

Correct: Roche 1H Sales Rose 4% On Year , Reported

24 lug 2025, 05:04 UTC

Utili

Roche 1H Net Pft Was Seen at CHF8.4B

24 lug 2025, 05:04 UTC

Utili

Roche 1H Net Pft CHF7.8B

24 lug 2025, 05:03 UTC

Utili

Roche 1H Oper Pft CHF12.0B

Confronto tra pari

Modifica del prezzo

Roche Holding AG Previsione

Sentiment

By Acuity

149 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat